TNF and rheumatoid arthritis: The csDMARDs are relatively cheap chemical agents consisting of small active-substance molecules and are used for decades in the treatment of RA, whereas bDMARDs, predominantly antibodies such as TNF-α inhibitors (TNFis), are expensive agents that target specific inflammatory pathways and have revolutionized the treatment options for RA patients since the first trial in 1993 [5].